Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dr Moro is in Amsterdam.
This amendment is NOT a termination of our licensing
agreement. In fact, Abbott co-authored a presentation in an
international cancer congress showing similar results to those pre
viously reported by BioCurex. The amendment shifts the research
and development effort to BioCurex, which in actuality has already
been the case for the past 2 years. Moreover, Abbott is the only
licensee allowed to sublicense the technology to third parties.
Thus, the termination or transfer of the Abbott license to
BioCurex or another licensee, would allow the recipient to sublicense
the RECAF tests to an unlimited number of sub-licensees,
thus removing the semi-exclusivity restrictions currently in
place. Since the termination/transfer of the Abbott license could
be accompanied by granting Abbott a sublicense under the same
terms they have now, this would allow BioCurex to “keep the cake
and eat it too”. The ability to sublicense to an unrestricted
number of companies has a considerable value to either BioCurex
or to anyone interested in acquiring the Abbott license.
Another important concession negotiated with Abbott was the
removal of manual tests from the semi-exclusivity terms of the
original licensing agreement. This, together with the exclusion
of manual assays from the Inverness licensing agreement, has
made possible the direct commercialization of the RECAF tests
directly by the company to smaller markets without sacrificing
the commercialization potential -- many times larger -- of its
licensees.
Finally, as our RECAF technology moves towards
commercialization, its value increases significantly. Keep in
mind that BioCurex is allowed to have three licensees: Inverness,
which signed its agreement earlier this year, Abbott and one
other company. Early negotiations are currently underway, and it
is quite conceivable that two companies will want to license our
RECAF technology. If that was the case, then Abbott’s position
might have to be vacated.
•
Accuracy
Stunningly, many other cancer tests may as well be coin tosses. Take prostate cancer for instance. Of all the 'positive' results yielded for a common PSA test, only 1/3 of them are actually accurate. The other 2/3 are false 'positives'. It gets worse though, because some of the 'negatives' for this test should actually be 'positive', meaning the patient has prostate cancer and may not even know it. All told, that PSA test is only about 40% accurate, which leads one to wonder if it's doing more harm than good.
When using the RECAF test to detect prostate cancer, the overall accuracy is cranked up to close to 90%.
And just to clarify, RECAF can screen for all cancers, since it's searching for that one certain molecule that only exists if cancer is present. Other tests in current use aim to indicate only one particular form of cancer.
Speed
As with any lab work, sending blood/serum samples from a doctor's office to a lab takes time, and manpower is needed to generate the test's results. That's just the way it is... or was, until BioCurex began to develop a rapid RECAF test - something that could be performed during an office visit with results being returned in a matter of minutes.
Since then, the device has been fully developed - and it works. The nearby image is a picture of a utilized test. Even to the amateur eye it's clear the rapid RECAF test can be highly accurate. While the lab version of the test is still utilized where a lab confirmation is preferred, the rapid test is a functional and fast screening test... something oncologists really don't have access to as of right now.
Cost
The cost to process most current cancer screening tests (materials, lab work, shipping, and the doctor's time) can vary from $75 to $800, depending on the test. If the expense isn't paid by the insurance company, it's paid out of the patient's pocket.
Having constructed a few versions of the rapid RECAF test already, BioCurex estimates their cancer diagnostic device will cost somewhere between $10 and $20.
While the price difference clearly favors use of the rapid test, there may be an even bigger, unrealized and unintended benefit to the RECAF test - it may actually be performed in those cases where the more expensive tests may not be approved by insurance companies, or declined by patients who would otherwise pay for such a test out of pocket.
Trading BOCX
The next steps for the company are to continue making progress towards the commercialization of the RECAF screening test. Nothing's been publicly confirmed yet, but in reviewing the company's history and news, one has to believe BioCurex has been lining up some deals and licensees.
With that being said, I've got two final points to make.
First, most of you know how biotech works - a huge portion of a stock's gains come before the biotech company makes its first cent.
Take Gilead Sciences (GILD) or Vertex Pharmaceuticals (VRTX) for instance. Gilead wasn't even close to being profitable until the fourth quarter of 2001, yet shares rallied from $1.00 to $7.00 over the nine years before that swing to a profit. Vertex has only posted six profitable quarters in the last 18 years (and none since 2003), yet VRTX shares are nearly 400% higher than they were 18 years ago.
That's not to say BioCurex is the next Gilead or Vertex. It might be - I just don't know. All I'm saying is with biotech, if you're not out in front, then you're automatically behind. That leads me to my other message....
Second, I can't stress enough how well the timing of this trading idea has lined up.
Like almost all stocks, BOCX suffered the bear market by pulling back from its 2007 peak around 90 cents. The tumble didn't stop until March of this year, as was also the case with the rest of the market. Welcome to the club. Since then, BOCX has been range-bound between 4 cents and 11 cents while the rest of the biotech market has rallied.
But wait a second... how is it a good thing if BioCurex trails?
The longer a stock can move in a range, the stronger the breakout is likely to be once it materializes. And, given the market's euphoria over biotech lately, I firmly believe it's more a matter of 'when' rather than 'if' for BioCurex.
I'd never deny that it was the swine flu craze and Dendreon's (DNDN) cancer vaccine update earlier in the year that jump-started the biotech frenzy, but make no mistake - the buzz has been sustained based on these biotech companies' own merits. I think BioCurex's day is coming soon too.
One of the supporting clues to the theory is today's somewhat mundane news release (below) from BioCurex. A couple of new directors were named to the board.
I'd be the first to say it's not a barn-burner as far as news goes, but having observed the BioCurex PR machine for a few years now, I'd also say this is likely to be the beginning of a string of company news that grows in importance as each press release is posted. See, the company has historically posted news in waves, and kicks those campaigns off with a mere 'stir the pot' kind of release like this one.
Anouncements Biocurex-37th Congress of the International Society for Oncodevelopmental Biology and Medicine Conference - 26/09/2009
ISOBM
Department of Clinical Biochemistry
The Royal Infirmary
Edinburgh EH3 9YW Telephone: 0131 242 6871
Fax: 0131 242 6882
Email: Stieber@klch.med.uni-muenchen.de
Events
37th Congress of the International Society for Oncodevelopmental Biology and Medicine Conference - 26/09/2009
The new onpet sight will be up and runnung shortly.This should churn up the media.The announcements of new foreighn partners.
The move into veterinary oncology adds a new focus area to Abbott's existing Animal Health research and product lines, which include diabetes, anesthesia, wound care, pain management and fluid therapy.
Software entity working on onpet web sight,setting up in house lab to perform test and foward results to vet's.varing interests from vet's from several country's with new partnerships needed.new director hooked up to venture capital.
Thanks for the reply crossbow.We need a copy of the insiders agreement with HLS.The hls stock divident and wsa take-over was to put preasure on HLS to come to terms with the insiders at IDS.We need to get a copy of that.Freedom of imformation act or if they ever file an 8k.As long as their is outstanding IDS shares.HLS can't file a clean 8K.
crossbow did you meet with pat downs and what was said?
Galaxy Energy Corp sym (GAX) (secret) $0.27 cents.Huge gas find.(secret)
--------------------------------------------------------------------------------
Galaxy Energy Corp sym (GAX) (secret) $0.27 cents.
Market cap 20 million.
Drilled 3 wells in Columbia river basin with exxel energy(canadian) symbol- (EXX).Keeping results under rap.Exxel just tried to buy out Galaxy's 25% interest for 45 million.No Deal says Galaxy.Must be real big find.
Galaxy sells powder river assets to Petrohunter for 50 million.Wow only 19 million market cap on this baby.Funds to be used to drill many more wells with Exxell in the Columbia river basin.Total 6300 acres.The Piceance Basin
The Company controls approximately 6,000 (1,500 net) undeveloped acres in the Piceance Basin through its wholly owned subsidiary, Dolphin Energy Corporation and in partnership with Exxel Energy Corp. The Company has received permits to drill on 10-acre spacing in its areas of current operation and will apply for approval to drill on 10-acre spacing throughout most of its acreage position.In the Biscuit Ranch 10-31D well, all completed zones within the overall interval from 7294' to 8462' have now been commingled, 2 3/8" production tubing has been installed,More: Experts have long believed a 125-mile-long and 60-mile-wide patch of land between the Columbia River and Wenatchee -- shaped like a massive footprint -- is rich in natural gas. So rich, in fact, its potential may be similar to the vast supplies of the Western Canadian Sedimentary Basin in Alberta and British Columbia.
General Inquiry (Windsor)
Tel.: 1 (519) 250-086 or 519 738 2881
Good Advice:
My felow comrads.I will give you some good advice.You are all over reacting on this one.This company is newly listed in the past year.I am from the area.This is a older company.The contracts are still in place.Newer company's have a hard time with financials especially wiyh oversees ties.Last month been Ramadan made it difficult.I am not saying there isn't something up with some pumping or shady deals.But the basics are still in place and this company is going to make alot of money.Get $500.00 and average down and all the pain will go away in a couple of weeks.Just don't over react account of a newspaper article.There hasn't been any concrete bad news yet.And yes this company is going to sell alot of concrete.
Good Advice:
My felow comrads.I will give you some good advice.You are all over reacting on this one.This company is newly listed in the past year.I am from the area.This is a older company.The contracts are still in place.Newer company's have a hard time with financials especially wiyh oversees ties.Last month been Ramadan made it difficult.I am not saying there isn't something up with some pumping or shady deals.But the basics are still in place and this company is going to make alot of money.Get $500.00 and average down and all the pain will go away in a couple of weeks.Just don't over react account of a newspaper article.There hasn't been any concrete bad news yet.And yes this company is going to sell alot of concrete.
Doreen can't tell you squat.anyone can report a company and have it investigated.give me charges that have been filed.
TD Ameritrade Numbers, August account openings are reported. ... 9/6/2006 7:19 AM EDT Authorities probe kickback allegations tied to short-selling. ...
www.thestreet.com/newsanalysis/wallstreet/10307793.html
Originally Posted by VMHS2009
Just posted on the Yahoo message board for AMTD:
"First off, feel free to read the links to stocklemon.com and get your laugh. But, then realize that the owner of that site now lives in Slovenia following a warrant for his arrest where he promptly left the country. The charge: securities fraud. I bet there is no laugh left now.
Secondly, Ameritrade will survive this serious situation, but if you are long AMTD, buyer beware. We could see massive negative impact over the next few quarters if Ameritrade is forced to cover their short at levels at or near the reset price of CSHD.
Laugh this off all you want, but perhaps AMTD is now the better candidate for shorting than CSHD. Remember, you heard it here first."
Check this out everyone.
http://www.realtimeassistant.com/purchase.php
Domain Name: HLSWORLDWIDE.COM
Registrar: NETWORK SOLUTIONS, LLC.
Whois Server: whois.networksolutions.com
Referral URL: http://www.networksolutions.com
Name Server: NS2.IDS-WORLDWIDE.COM
Name Server: CP.IDS-WORLDWIDE.COM
Status: REGISTRAR-LOCK
EPP Status: clientTransferProhibited
Updated Date: 25-Jul-2006
Creation Date: 08-Jul-2006
Expiration Date: 08-Jul-2007
>>> Last update of whois database: Thu, 27 Jul 2006 21:18:11 EDT <<<
http://www.hlsworldwide.com
check out the new HLS site.Up and Running.
I have done some research on this company.I have confirmed ste ordered 100,00 bio flash units and have been receiving shipments from hls.there is a big bio flash demo for dealers in orlando tomorrow.the divi shares have showed up in everyone's account even though they have no value.do you think a crook would go to this much trouble.He would have to be crazy to say he sighned a contract with the U.S. Navy.I have also confirmed their security division has a backlog of 700 homes each with a 3 yr maintenance ageeement at 85% profit margin.